Otonomy Inc (OTIC):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Otonomy Inc (OTIC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9803
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:56
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Otonomy Inc (Otonomy) develops and markets treatments for diseases and disorders of the ear. The company’s Otiprio is the US FDA approved ciprofloxacin otic suspension indicated during tympanostomy tube placement surgery in pediatric patients. Its pipeline portfolio encompasses Otividex for the treatment of Meniere’s disease (Phase 3); OTO-313 for the treatment of tinnitus (Phase 1/2); OTO-5XX for the treatment of cisplatin-induced hearing loss (Phase 2), OTO-413 for the treatment of synaptopathy hearing loss; and OTO-6XX for the treatment of severe hearing loss. Otonomy is also investigating a preclinical program on sensorineural hearing loss including age-related hearing loss. It employs its proprietary formulation technology that uses a thermosensitive gel and drug microparticles for enabling single dose treatment by a physician. Otonomy is headquartered in San Diego, California, the US.

Otonomy Inc (OTIC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Otonomy Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Otonomy Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Otonomy Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Otonomy Acquires Assets and Patent Rights From NeuroSystec 11
Venture Financing 12
Otonomy Raises US$49 Million In Series D Venture Financing 12
Otonomy Raises US$46 Million In Series C Venture Financing 14
Partnerships 16
Otonomy Enters into Co-Promotion Agreement with Mission Pharmacal 16
Licensing Agreements 17
Otonomy Enters into Licensing Agreement with Ipsen 17
Otonomy Enters into Licensing Agreement with Durect 18
Equity Offering 19
Otonomy Raises USD115 Million in Public Offering of Shares 19
Otonomy Raises USD86 Million in Public Offering of Shares 21
Otonomy Completes Underwriters Exercise of Over-Allotment Option of IPO for USD115 Million 23
Otonomy Inc – Key Competitors 25
Otonomy Inc – Key Employees 26
Otonomy Inc – Locations And Subsidiaries 27
Head Office 27
Recent Developments 28
Strategy And Business Planning 28
Nov 27, 2017: Otonomy Announces Plan to Focus Resources on Development Programs 28
Financial Announcements 29
Nov 05, 2018: Otonomy reports third quarter 2018 financial results and provides corporate update 29
Aug 08, 2018: Otonomy reports second quarter 2018 financial results and provides corporate update 31
May 09, 2018: Otonomy Reports First Quarter 2018 Financial Results and Provides Corporate Update 33
Mar 08, 2018: Otonomy Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update 34
Nov 08, 2017: Otonomy Reports Third Quarter 2017 Financial Results and Provides Corporate Update 36
Aug 03, 2017: Otonomy Reports Second Quarter 2017 Financial Results and Provides Corporate Update 37
May 04, 2017: Otonomy Reports First Quarter 2017 Financial Results and Provides Corporate Update 39
Mar 02, 2017: Otonomy Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 41
Product News 43
07/18/2017: Otonomy Announces FDA Acceptance of OTIPRIO Supplemental New Drug Application Filing for Acute Otitis Externa 43
Clinical Trials 44
Nov 08, 2017: Otonomy Reports Positive Results from AVERTS-2 Phase 3 Trial of OTIVIDEX in Patients with Ménière’s Disease 44
Aug 30, 2017: Otonomy Reports Results for AVERTS-1 Phase 3 Trial for OTIVIDEX in Patients with Menieres Disease 45
Jun 22, 2017: Otonomy Announces Successful End-of-Phase 2 Review by FDA for OTIPRIO in Acute Otitis Media with Tympanostomy Tubes 46
Jun 20, 2017: Otonomy to Host Key Opinion Leader Meeting for Investors on Meniere’s Disease 47
May 12, 2017: Otonomy Announces OTIPRIO Data Presentation and Symposium at the American Society of Pediatric Otolaryngology Annual Meeting 48
Jan 19, 2017: Otonomy Initiates Patient Enrollment in Phase 2 Clinical Trial of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss 49
Jan 05, 2017: Otonomy Announces Positive Top-Line Results from Phase 3 Clinical Trial of OTIPRIO in Patients with Acute Otitis Externa 50
Other Significant Developments 51
Jan 09, 2018: Otonomy Provides Corporate and Product Pipeline Update 51
Sep 13, 2017: Otonomy Provides Business and Financial Update 53
Jan 09, 2017: Otonomy Provides Corporate and Product Pipeline Update 54
Appendix 56
Methodology 56
About GlobalData 56
Contact Us 56
Disclaimer 56

List of Tables
Otonomy Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Otonomy Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Otonomy Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Otonomy Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Otonomy Acquires Assets and Patent Rights From NeuroSystec 11
Otonomy Raises US$49 Million In Series D Venture Financing 12
Otonomy Raises US$46 Million In Series C Venture Financing 14
Otonomy Enters into Co-Promotion Agreement with Mission Pharmacal 16
Otonomy Enters into Licensing Agreement with Ipsen 17
Otonomy Enters into Licensing Agreement with Durect 18
Otonomy Raises USD115 Million in Public Offering of Shares 19
Otonomy Raises USD86 Million in Public Offering of Shares 21
Otonomy Completes Underwriters Exercise of Over-Allotment Option of IPO for USD115 Million 23
Otonomy Inc, Key Competitors 25
Otonomy Inc, Key Employees 26

List of Figures
Otonomy Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Otonomy Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Otonomy Inc (OTIC):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • SHL TeleMedicine Ltd (SHLTN):企業の財務・戦略的SWOT分析
    SHL TeleMedicine Ltd (SHLTN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Philippine Long Distance Telephone Co (TEL):企業の財務・戦略的SWOT分析
    Philippine Long Distance Telephone Co (TEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key streng …
  • Worthington Industries Inc:企業の戦略・SWOT・財務分析
    Worthington Industries Inc - Strategy, SWOT and Corporate Finance Report Summary Worthington Industries Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Indequity Group Limited:企業の戦略・SWOT・財務分析
    Indequity Group Limited - Strategy, SWOT and Corporate Finance Report Summary Indequity Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • PowerSouth Energy Cooperative:企業の戦略的SWOT分析
    PowerSouth Energy Cooperative - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Universal Health Services Inc (UHS):製薬・医療:M&Aディール及び事業提携情報
    Summary Universal Health Services Inc (UHS) is a healthcare service provider the offers acute care and behavioral health services. The center provides services such as general and specialty surgery, internal medicine, obstetrics, oncology, diagnostic care, coronary care, emergency room care, radiolo …
  • Apache Corp (APA):石油・ガス:M&Aディール及び事業提携情報
    Summary Apache Corp (Apache) is an independent upstream energy company, which carries out exploration, development and production of natural gas, crude oil and natural gas liquids (NGLs). It has onshore and offshore asset base consisting of operations in the Permian Basin, the Anadarko basin in west …
  • FirstRand Private Bank:企業の戦略・SWOT・財務情報
    FirstRand Private Bank - Strategy, SWOT and Corporate Finance Report Summary FirstRand Private Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Antitope Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Antitope Ltd (Antitope), a subsidiary of Abzena Plc is a life science company that research and develops technologies for various therapeutic areas. The company’s iTope technology is used to identify peptides; and T Cell Epitope Database is used for screening amino acid sequences from antibo …
  • Bio-Modeling Systems SAS:製薬・医療:M&Aディール及び事業提携情報
    Summary Bio-Modeling Systems SAS (BM Systems) is a biotechnology company that discovers and develops novel diagnostic, therapeutic and prevention solutions. The company owns an operational mechanisms-based medicine platform known as computer-assisted deductive integration (CADI), which is used in th …
  • Telus Corp (T):企業の財務・戦略的SWOT分析
    Telus Corp (T) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Merafe Resources Ltd:企業の戦略・SWOT・財務分析
    Merafe Resources Ltd - Strategy, SWOT and Corporate Finance Report Summary Merafe Resources Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Sky plc:企業の戦略・SWOT・財務情報
    Sky plc - Strategy, SWOT and Corporate Finance Report Summary Sky plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Nordic American Tankers Ltd (NAT):石油・ガス:M&Aディール及び事業提携情報
    Summary Nordic American Tankers Limited (NAT) is a tanker company. It transports crude oil through its fleet of double-hull Suezmax tankers. The company operates its vessels on bareboat charters, time charters, and spot charters. NAT’s tankers are capable of carrying high volumes of oil and able to …
  • Applied Maths NV:医療機器:M&Aディール及び事業提携情報
    Summary Applied Maths NV (Applied Maths), a subsidiary of bioMerieux SA, is a bioinformatics company that designs, develops and markets bioscience software products. The company offers software products such as bionumerics, gelcompar II, bionumerics server and bionumerics calculation engine. Its bio …
  • MDU Resources Group, Inc.:企業の戦略・SWOT・財務分析
    MDU Resources Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary MDU Resources Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • National Gypsum Co:企業の戦略・SWOT・財務情報
    National Gypsum Co - Strategy, SWOT and Corporate Finance Report Summary National Gypsum Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • NorthWestern Corporation:企業の戦略・SWOT・財務分析
    NorthWestern Corporation - Strategy, SWOT and Corporate Finance Report Summary NorthWestern Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • NicOx SA (COX):企業の財務・戦略的SWOT分析
    Summary NicOx SA (NicOx) is an ophthalmology company that develops solutions to help maintain vision and improve ocular health. The company’s products include Vyzulta, a latanoprostene bunod ophthalmic solution; and Zerviate, a cetirizine ophthalmic solution. It offers products in the therapeutic ar …
  • Neuralstem Inc (CUR)-医療機器分野:企業M&A・提携分析
    Summary Neuralstem Inc (Neuralstem) is a developer of medicines for nervous system diseases. The company offers cell therapy treatment for ALS, ischemic stroke, spinal cord injury, multiple sclerosis, optic neuritis, Alzheimer’s disease, traumatic brain injury, peripheral nerve injury, diabetic neur …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆